Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Eric E. Easom
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 21
- Beta
- -0.99
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 13.76
Financials
Net Income
$-8.19MEBITDA
$-8.19MFree Cash Flow
$-7.00MEPS (diluted)
$-0.18Shares Outstanding (diluted)
44.76M+218.6%Operating Expenses
$8.90MCash & Debt
$78.39MDividend per Share
$0.66Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-35.17M | $-1.16 |
| 2024 | $0.00 | $-51.32M | $-1.72 |
| 2023 | $0.00 | $-64.73M | $-2.74 |
| 2022 | $0.00 | $-40.96M | $-2.79 |
| 2021 | $0.00 | $-21.54M | $-1.50 |
| 2020 | $0.00 | $-13.60M | $-0.78 |
| 2019 | $0.00 | $-33.81M | $-0.30 |
Valuation
ANTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
85-15.00%Social Signal Score
Mentions (2)
- Newsseekingalpha.com·5h ago·Negative
AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver I rate AN2 Therapeutics a speculative buy, with a risk-adjusted base-case valuation of approximately $12 per share versus its September 18 closing price of $5.05. Epetraborole failed in treatment-refractory MAC lung disease, but its dose-dependent and reversible reductions in red-cell parameters could become therapeutic in polycythemia vera. Human and nonhuman-primate data support the erythroid effect, but EBO-PV-201 must demonstr
View source ↗ - Newsbusinesswire.com·5d ago·Neutral
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4) MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to Cameron Trenor, M.D., the Company's newly-appointed Chief Medical Officer.The inducement awards consist of a non-qualified stock option to purchase 233,333 sha…
View source ↗
Earnings
Thu, Nov 5(in 6 weeks)
Consensus estimate $-0.20 per share
Typical surprise -20.8% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.18 vs $-0.24beat
- Mon, May 11$-0.29 vs $-0.23miss
- Tue, Mar 17$-0.29 vs $-0.24miss
- Wed, Nov 12$-0.31 vs $-0.23miss
- Tue, Aug 12$-0.21 vs $-0.31beat
- Tue, May 13$-0.35 vs $-0.26miss
Estimates and results for ANTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ANTX officers and directors.
- Bought
- $12k
- Sold
- $345k
1 trade
12 trades
- Readnour Robin Shanesold
- Readnour Robin Shanesold
- Readnour Robin Shanesold
- Readnour Robin Shanesold
- Readnour Robin Shanesold
- Readnour Robin Shanesold
- Williams Sarah Joannesold
- Fitzpatrick Margaret Mbought
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ANTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.